Subscribe: Nature Reviews Cardiology - Issue - science feeds
Added By: Feedage Forager Feedage Grade A rated
Language: English
artery  cardiology  cardiovascular  clinical  disease  failure  heart failure  heart  new  patients  precision medicine  stem cells 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Nature Reviews Cardiology - Issue - science feeds

Nature Reviews Cardiology - Issue - science feeds

Nature Reviews Cardiology provides physicians and academics with authoritative and topical discussions of key developments in the field.


Device therapy: ICDs in nonischaemic heart failure


The use of an implantable cardioverter–defibrillator (ICD) in patients with systolic heart failure not caused by coronary artery disease does not reduce all-cause mortality. This finding comes from the DANISH trial, which was presented at the 2016 ESC Congress in Rome, Italy, and simultaneously published

Hypertension: Blood-pressure lowering in type 2 diabetes


In patients with type 2 diabetes mellitus and no history of cardiovascular disease, lowering blood pressure beyond levels currently recommended in clinical guidelines might be associated with reduced risk of cardiovascular disease. This finding comes from a study of 187,106 patients in the Swedish national

Valvular disease: vWF testing for paravalvular regurgitation during TAVI


Prolonged closure time with adenosine diphosphate (CT-ADP), a point-of-care test of haemostasis, and the presence of defects in high-molecular-weight (HMW) multimers of von Willebrand factor (vWF) are both predictive of aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI). These novel approaches for monitoring paravalvular

Diabetes: PCSK9 inhibition is not associated with new-onset diabetes


Treatment with the PCSK9 inhibitor alirocumab is not associated with transition to new-onset diabetes mellitus, according to a pooled analysis of 10 phase III clinical trials. Given the results from clinical studies showing that statin therapy modestly increases the risk of developing diabetes, and because

Interventional cardiology: Preventing heart failure after STEMI with a cardiac matrix


Intracoronary delivery of an injectable bioabsorbable alginate, known as the bioabsorbable cardiac matrix (BCM), does not decrease adverse left ventricular (LV) remodelling or cardiac events at 6 months in patients who underwent stent placement after ST-segment elevation myocardial infarction (STEMI). These findings from the PRESERVATION

Anticoagulation therapy: Appropriate dosing of apixaban


In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with atrial fibrillation, those with two or more dose-reduction criteria (aged ≥80 years, weight ≤60 kg, creatinine level ≥1.5 mg/dl) received 2.5 mg of apixaban twice daily, instead of the full dose

Hypertension: Update on renal artery denervation


Patients with isolated systolic hypertension (ISH) have less pronounced reductions in blood pressure (BP) after sympathetic renal artery denervation than patients with combined systolic–diastolic hypertension (CH), according to findings from a pooled analysis of data from the SYMPLICITY HTN-3 clinical trial and the Global SYMPLICITY

Surgery: Reliability of radial artery in CABG surgery


The 20-year angiographic outcome of using the radial artery in CABG surgery is similar to that with the gold standard internal thoracic artery (ITA), according to a prospective, observational study published in the Journal of the American College of Cardiology. Although the use of

Public health: What's app in emergency cardiovascular care?


In a new scientific statement, the AHA addresses the revolution brought by smartphones and social media to the field of emergency cardiology. New, attractive opportunities exist alongside new dangers. Information is currently delivered to the Internet without control. Trustworthy medical information is needed: it is time for scientific societies to take action.

Atrial fibrillation: FIRE or ICE? Cryoablation not inferior, not superior


The primary analysis of FIRE AND ICE demonstrated that cryoablation was noninferior to radiofrequency ablation for the primary efficacy end point of first documented clinical failure. Secondary analysis suggested that cryoablation had advantages over radiofrequency ablation in terms of rehospitalizations and repeat procedures; however, the validity of these results must be questioned.

Expandable progenitors from induced pluripotent stem cells


We read with interest the Review by Wu et al. (Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat. Rev. Cardiol. 13, 333–349; 2016), which provided an insight into precision medicine aimed at successful drug screening

Alternative approaches to generating cardiomyocytes are under development


We would like to thank Masuda et al. for their Correspondence (Expandable progenitors from induced pluripotent stem cells. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.129) on our Review (Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat. Rev. Cardiol.13

Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation


Atrial fibrillation (AF) is an extremely prevalent arrhythmia that presents a wide range of therapeutic challenges. AF usually begins in a self-terminating paroxysmal form (pAF). With time, the AF pattern often evolves to become persistent (nonterminating within 7 days). Important differences exist between pAF and

Precision medicine in cardiology


The cardiovascular research and clinical communities are ideally positioned to address the epidemic of noncommunicable causes of death, as well as advance our understanding of human health and disease, through the development and implementation of precision medicine. New tools will be needed for describing the

Global cardiovascular protection in chronic kidney disease


The development and progression of cardiovascular disease (CVD) and renal disorders are very closely related. In patients with chronic kidney disease (CKD), therapies proven to protect the cardiovascular and renal systems simultaneously are generally used only at low doses or not at all. In particular,

Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease


Atherothrombosis is the common underlying process for numerous progressive manifestations of cardiovascular disease, including coronary artery disease (CAD) and cerebrovascular disease (CVD). Antiplatelet therapy is the cornerstone of pharmacological management in patients with atherothrombosis. Over the past 20 years, major advances in antiplatelet pharmacotherapy have

2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?


Heart failure (HF) is a global epidemic affecting millions of individuals worldwide. Although important progress has been made in the management of HF, this condition remains a common cause of morbidity and death. Since the publication of the previous sets of guidelines for the management